TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02653339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qufeng Shengshi Fang and Loratadine
Description: The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD
Study: NCT02653339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qufeng Shengshi Fang and Loratadine
Description: The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine
Description: The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The control group patients are treated with Loratadine by oral, 10mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The control group patients are treated with Loratadine by oral, 10mg QD
Study: NCT02103062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Study: NCT00915538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pMDI budesonide/formotrol 160/4.5 is in group 1
Description: The asthmatic subjects will receive budesonide/formoterol pMDI 160/4.5 pMDI 2 inhalations used in conventional fashion, and have pulmonary function measured over 12 hours who are expected to show bronchodilation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Symbicort 160/4.5 plus Aerochamber Plus included in group 2
Description: Symbicort 160/4.5 2 inhalations will be administered through a valved holding chamber, Aerochamber Plus, Pulmonary functions will be measured over 12 hours in asthmatic subjects who are expected to show bronchodilation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symbicort 160/4.5 plus Aerochamber Plus included in group 2
Description: Symbicort 160/4.5 2 inhalations will be administered through a valved holding chamber, Aerochamber Plus, Pulmonary functions will be measured over 12 hours in asthmatic subjects who are expected to show bronchodilation.
Study: NCT00343109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu intracellular domain protein
Description: Given ID

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given ID

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: synthetic tumor-associated peptide vaccine therapy
Description: Given ID
Study: NCT00690430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pasireotide
Description: Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed
Study: NCT01687881

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chiropractic
Description: Chiropractic Spinal Manipulative Therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Chiropractic
Description: Sham manipulation
Study: NCT04650997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: Knee eccentric exercise with sham or focused extrocorporeal shockwave therapy for 12 weeks

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Eccentric exercise
Description: Knee eccentric exercise with sham or focused extrocorporeal shockwave therapy for 12 weeks
Study: NCT01090921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle.~Dexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone.
Study: NCT00742924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT03565822

Intervention type: OTHER
Group type: OTHER
Intervention: Interview
Description: individual interview and/or focus group Grounded theory qualitative analysis of data related to socio-demographic and child characteristics data First, data will be prepared for qualitative analysis. Digital audio files from the focus groups will be transcribed verbatim and questionnaire data will be entered into an Excel/word data file. Second, focus group data will be qualitatively analyzed using the constant comparative process. A qualitative data analysis program, NVivo11 (Victoria, Australia/ QSR International)) will be used to assist with this coding process.
Study: NCT01838460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual nicotine tablets
Description: 6 mg = 3 tablets

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smokeless tobacco
Description: Swedish type moist snuff

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smokeless tobacco
Description: Swedish type moist snuff

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smokeless tobacco
Description: Swedish type moist snuff

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smokeless tobacco
Description: Swedish type moist snuff
Study: NCT01856842

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography and embolotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography and embolotherapy
Study: NCT02533401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered IV at 250 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered IV at 25 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered IV at 375 mg/m\^2 on Day 1 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
Study: NCT01422512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal influenza vaccine
Description: Subjects received one single IM dose of trivalent Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
Study: NCT02899806

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Written Information
Description: A written information on peridural anesthesia is delivered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Information
Description: A written information on peridural anesthesia is delivered
Study: NCT01611740

Intervention type: PROCEDURE
Intervention: Analysis of the heart rate and respiratory characteristics / Telemonitoring system prototype developed by INSERM U-642
Description: Telemonitoring system prototype developed by INSERM U-642 with analysis of :~* the variability of the cardiac cycle duration ;~* the variability of respiratory cycle amplitude and duration ;~* and their relationships.
Study: NCT02843438

Intervention type: OTHER
Group type: OTHER
Intervention: Fluorescein angiography

Intervention type: OTHER
Group type: OTHER
Intervention: Dilated fundus examination

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Toxoplasmosis serology

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-toxoplasmosis treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-inflammatory treatments

Intervention type: OTHER
Group type: OTHER
Intervention: Puncture in anterior chamber
Study: NCT03440567

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous hematopoietic stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV
Study: NCT06554119

Intervention type: PROCEDURE
Intervention: Huanlei Huang
Description: tricuspid valve replacement or plasty

Intervention type: PROCEDURE
Intervention: Huanlei Huang
Description: tricuspid valve replacement or plasty
Study: NCT01320345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: 145 mg tablet of fenofibrate administered once daily for 36 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inert lactose placebo
Description: Insert lactose tablet matching active tablet administered once daily for 36 months.
Study: NCT01591434

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AQUACEL®
Description: Dressing to be changed as clinically needed or at least every seven days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AQUACEL® Extra™
Description: Dressing to be changed as clinically needed or at least every seven days.
Study: NCT01681667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
Study: NCT03987711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No oral anticoagulation
Description: No oral anticoagulation
Study: NCT01789359

Intervention type: OTHER
Group type: OTHER
Intervention: Blueberry Juice
Description: Dietary intervention
Study: NCT03087604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic epidural block
Description: Thoracic epidural block with epidural placed with a loss of resistance technique alone.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural block
Description: Thoracic epidural block with epidural placed with a loss of resistance technique alone.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Nerve stimulation
Description: In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall.stimulating peripheral nerve catheters(19 Ga. x 90 cm StimuCath® Continuous Nerve Block Catheter with SnapLock™ Adapter (Arrow by Teleflex Medical, Morrisville, NC), and stimulation will be achieved using a B Braun Stimuplex HNS12 Nerve Stimulator product id 4892098.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solution For Thoracic epidural block
Description: Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solution For Thoracic epidural block
Description: Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine
Study: NCT01393899

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: oral tablets twice daily
Study: NCT02899806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Information
Description: A link to a video explaining peridural anesthesia is delivered to the pregnant woman. The patient can watch the video several times.
Study: NCT03126578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731
Description: LEO 32731 is being developed by LEO Pharma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Benzodiazepine
Study: NCT01393899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: oral tablets twice daily
Study: NCT01460706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]DOTATOC
Description: 120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
Study: NCT05789459

Intervention type: DEVICE
Intervention: Stapler
Description: Stapler

Intervention type: OTHER
Intervention: Suture
Description: Suture
Study: NCT02122146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06664178
Description: Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06664178
Description: Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
Study: NCT02001324

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web-based data collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based data collection
Study: NCT02735421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABPO Forte Gel
Description: Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABPO Forte Gel
Description: Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Participants applied placebo matched to ABPO Forte gel topically to the affected areas once daily for 24 weeks in Part 1 and 48 weeks in Part 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Participants applied placebo matched to ABPO Forte gel topically to the affected areas once daily for 24 weeks in Part 1 and 48 weeks in Part 2.
Study: NCT03086538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed is a multitarget antifolate (MTA) whose mechanism of action relies mainly on the inhibition of TS, with weaker secondary effects on glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), leading to impairment of DNA synthesis and repair.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva 100Mg Tablet
Description: Erlotinib (tarceva) is oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
Study: NCT01752725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiCision®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultracision® Har-monic Scalpel(Ethicon)
Study: NCT03770676

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium-fortified biscuits
Description: Selenium-fortified biscuits, fortified with selenium-enriched yeast (approx. 60 mcg selenium per day, for 14 days). One of three novel flavours.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium-fortified biscuits
Description: Selenium-fortified biscuits, fortified with selenium-enriched yeast (approx. 60 mcg selenium per day, for 14 days). One of three novel flavours.
Study: NCT01145781

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw. Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw. Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
Study: NCT01290042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 181
Description: Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for AMG 181
Description: Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
Study: NCT04212715

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic SABR with intra-prostatic SABR
Description: SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions to MR nodule
Study: NCT02176200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® Respimat®, low inspiratory flow rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® Respimat®, low inspiratory flow rate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® Respimat®, medium inspiratory flow rate
Study: NCT03770676

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium-fortified biscuits
Description: Selenium-fortified biscuits, fortified with selenium-enriched yeast (approx. 60 mcg selenium per day, for 14 days). One of three novel flavours.
Study: NCT00432913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic Acid (EPA)
Description: Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)
Study: NCT02176200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® Respimat®, medium inspiratory flow rate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® Respimat®, high inspiratory flow rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® Respimat®, high inspiratory flow rate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® HFA-MDI, low inspiratory flow rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® HFA-MDI, low inspiratory flow rate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® HFA-MDI, medium inspiratory flow rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® HFA-MDI, medium inspiratory flow rate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® HFA-MDI, high inspiratory flow rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® HFA-MDI, high inspiratory flow rate
Study: NCT04178928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: investigate the effect of replacement therapy with levothyroxine on cardiovascular risk factors in children with SCH.
Study: NCT03118336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10Mg Tab
Description: 1 tablet of 10 milligrams per bone 1 time a day during 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin 10Mg Tab
Description: 1 tablet of 10 milligrams per bone 1 time a day during 12 weeks
Study: NCT01591408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG biofeedback
Description: EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EEG biofeedback
Description: EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.
Study: NCT00886769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab was supplied in individual 6 mL glass vials each containing 150 mg canakinumab powder as a lyophilized cake. Each reconstituted vial provided 150mg of canakinumab per 1 mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided in individual 6 mL glass vials each containing 150 mg placebo powder matching canakinumab as a lyophilized cake. Each reconstitued vial provided 150mg of placebo per 1 mL.
Study: NCT05231759

Intervention type: DEVICE
Intervention: L'DISQ
Study: NCT00405730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac 1mg/ml eye drops, suspension
Description: One drop in the study eye 3 times daily for 23 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Trometamol 5 mg/ml eye drops, solution
Description: One drop in the study eye 3 times daily for 23 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac vehicle eye drops
Description: One drop in the study eye 3 times daily for 23 days
Study: NCT03456258

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Complete blood count
Description: To measure hemoglobin difference and serum ferritin levels .

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Complete blood count
Description: To measure hemoglobin difference and serum ferritin levels .